New to Meducation?
Sign up
Already signed up? Log In

Category

10
1
10

BCU Think Tank 1 | 07 - Systemic Therapy of Metastatic Disease

www.BreastCancerUpdate.com/ThinkTank – Proceedings from a Clinical Investigator “Think Tank"  
Dr Neil Love
over 9 years ago
10
1
10

SABCS Spin-Off | 06 - Buzdar

For postmenopausal women with ER-positive, metastatic disease, tamoxifen, an aromatase inhibitor or fulvestrant are essentially equivalent choices.  
Dr Neil Love
over 9 years ago
11
1
14

SABCS Spin-Off | 06 - Hudis

Outside a protocol setting, dose-dense AC ->paclitaxel, administered every two weeks with growth factors, with trastuzumab during and following the paclitaxel, provides the best potential risk/benefit profile for women with HER2-positive, node-positive disease.  
Dr Neil Love
over 9 years ago
12
1
23

SABCS Spin-Off | 06 - Dixon

Neoadjuvant therapy with an aromatase inhibitor provides the best potential risk/benefit profile for postmenopausal women with HER2-negative, strongly ER-positive and PR-positive disease.  
Dr Neil Love
over 9 years ago
0
1
28

SABCS Spin-Off | 06 - Mackey

Outside a protocol setting, a combination of endocrine therapy and trastuzumab provides the best potential risk/benefit profile for women with ER-positive, HER2-positive metastatic disease.  
Dr Neil Love
over 9 years ago
1
1
25

SABCS Spin-Off | 06 - Tripathy

Outside a protocol setting, the combination of lapatinib and capecitabine provides the best potential risk/benefit profile for women with ER-negative, PR-negative, HER2-positive, node-positive disease with cancer recurrence after AC->TH.  
Dr Neil Love
over 9 years ago
5
1
14

BCU Think Tank 2 | 06 - Section 5

Treatment of HER2-Positive Disease  
Dr Neil Love
over 9 years ago
11
1
10

BCU 6 | 06 - MBCC Tumor Panel

Miami Breast Cancer Conference Tumor Panel Discussion on Systemic Therapy of Metastatic Disease  
Dr Neil Love
over 9 years ago
6
1
20

HCCU1 2007 | 62yo ruptured HCC followed by sorafenib for recurrent disease

HCCUpdate.com – 62yo, emergency hepatic lobectomy for ruptured HCC; sorafenib for recurrent disease. Interviews conducted by Neil Love, MD. Produced by Research To Practice.  
Dr Neil Love
over 9 years ago
2
1
18

HOUJC1 2009 | Case 3

ResearchToPractice.com/HOUJC109 – Case 3: 75yo woman initially treated with R-CHOP for Stage IV diffuse large B-cell lymphoma and then with R-EPOCH for recurrent disease. Interviews conducted by Neil Love, MD. Produced by Research To Practice.  
Dr Neil Love
over 9 years ago
6
1
14

MTPB4 2007 | Case 11 presented by Srinath Sundararaman, MD, MS

MeetTheProfessors.com – Case from the practice of Srinath Sundararaman, MD, MS; 54-year-old with 6-cm, triple-negative IDC and palpable lymph nodes, significant residual disease in the axilla presented to Drs Wolff and Burris  
Dr Neil Love
over 9 years ago
4
1
15

MTPC1 2007 | Case 03 presented by Michael A Schwartz, MD

MeetTheProfessors.com – 63yo w/prim. sigmoid, synch. liver mets, extensive pelvic disease; diverting colostomy; rcvd FOLFOX w/bev; CEA level dropped by 80% after 3 cycles; no tumor on sigmoidoscopy/laparotomy after 6 cycles; colostomy closed, began cape  
Dr Neil Love
over 9 years ago
9
1
30

MTPC1 2007 | Case 08 presented by Daniel J Moriarty, MD

MeetTheProfessors.com – 62yo w/squamous cell carc. 3-4cm above anal verge; rcvd neoadj rad. therapy & 5-FU/mitomycin; tumor was not visible/palpable after chemo but seen on ultrasound; AP resection revealed submucosal disease, with 5/19 positive nodes  
Dr Neil Love
over 9 years ago
13
1
12

MTPC1 2007 | Case 12 presented by William G Reeves, MD

MeetTheProfessors.com – 54yo in whom a colonoscopy revealed both rectal and transverse colon lesions; PET-CT scan did not show any distant disease or nodal involvement  
Dr Neil Love
over 9 years ago
0
1
53

MTPC1 2007 | Case 13 presented by Philip Glynn, MD

MeetTheProfessors.com – 48yo w/res. of 3-cm, moderately well-diff. tumor into subserosa, 4/7+ nodes, 2 palp. liver lesions; biopsy revealed met disease; rcvd chemo/wedge resection of liver w/cryotherapy; rcvd 6mo 5-FU/leu, doing well 12 years later  
Dr Neil Love
over 9 years ago
3
1
27

MTPL1 2007 | Case 03 presented by Kenneth R Hoffman

MeetTheProfessors.com – 73-year-old underwent thoracotomy, Stage IIIA left lower lobe adenocarcinoma w/1 pos. mediastinal lymph node; 4 cycles of adj. carbo/pac > adj. radiation therapy, prophylactic cranial irradiation; diagnosed w/metastatic disease  
Dr Neil Love
over 9 years ago
7
1
51

MTPL1 2007 | Case 07 presented by Mohan Menon, MD

MeetTheProfessors.com – 35-year-old w/a 5-cm left hilar mass w/mediastinal adenopathy on CT/PET; received 6 cycles of carboplatin/docetaxel & radiation therapy; biopsy later revealed adrenal gland metastatic disease; underwent a laparoscopic adrenalectomy  
Dr Neil Love
over 9 years ago
10
1
9

PCUTT1 2007 | Multimodality Therapy of Localized Disease

ProstateCancerUpdate.com/ThinkTank – Proceedings from a Clinical Investigator “Think Tank.” Multimodality Therapy of Localized Disease. Interviews conducted by Neil Love, MD. Produced by Research To Practice.  
Dr Neil Love
over 9 years ago
11
1
9

PCUTT1 2007 | Treatment of PSA-Only Disease

ProstateCancerUpdate.com/ThinkTank – Proceedings from a Clinical Investigator “Think Tank.” Treatment of PSA-Only Disease. Interviews conducted by Neil Love, MD. Produced by Research To Practice.  
Dr Neil Love
over 9 years ago
12
1
20

PCUTT1 2007 | Chemotherapy for Hormone-Refractory, Metastatic Disease

ProstateCancerUpdate.com/ThinkTank – Proceedings from a Clinical Investigator “Think Tank.” Chemotherapy for Hormone-Refractory, Metastatic Disease. Interviews conducted by Neil Love, MD. Produced by Research To Practice.  
Dr Neil Love
over 9 years ago